Medannex is an award-winning Scottish biopharmaceutical company committed to unlocking the therapeutic potential of targeting annexin-A1. Our goal is to create a first-in-class therapy to improve the lives of people impacted by cancers and autoimmune diseases. Following a recent Series B fundraise, and supported by both the Scottish Investment Bank and Innovate UK, Medannex is collaborating with world-leading clinical experts to explore the huge therapeutic and commercial potential of our patent-protected immunomodulatory technology.
View Top Employees from Medannex LtdWebsite | http://medannex.org/ |
Employees | 11 (11 on RocketReach) |
Founded | 2009 |
Phone | +44 131 357 4251 |
Technologies |
JavaScript,
PHP,
Font Awesome
+8 more
(view full list)
|
Industry | Biotechnology Research, Business Services General, Biotechnology, Business Services, Science and Engineering, Clinical Trials, Health Care |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 54171 Companies, NAICS Code 541 Companies, NAICS Code 5417 Companies, NAICS Code 54 Companies, NAICS Code 541713 Companies |
Looking for a particular Medannex Ltd employee's phone or email?
Ian Abercrombie is the CEO of Medannex Ltd.
11 people are employed at Medannex Ltd.
The NAICS codes for Medannex Ltd are [54171, 541, 5417, 54, 541713].
The SIC codes for Medannex Ltd are [87, 873].